TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06178718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.
Study: NCT03828890

Intervention type: OTHER
Group type: OTHER
Intervention: Screening eye exam using Optos technology
Description: Retinal imaging using Optos technology to identify Diabetic Retinopathy
Study: NCT01012947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Usual Care
Description: Usual care participants in the group A received no additional services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Telephone, Bimonth
Description: Participants in the group B received bimonthly telephonic care management based on manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Telephone, Month
Description: Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Visit, Bimonth
Description: Participants in the group D received health educator-initiated visit counseling bimonthly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling Visit, Reward
Description: Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
Study: NCT03299348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AgingPLUS
Description: The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control Group
Description: The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) four major health conditions that affect the lives of many middle-aged and older adults (e.g., cardiovascular disease, cancer, type 2 diabetes; clinical depression); and (b) how these conditions can be managed successfully.
Study: NCT04802304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Bias Treatment
Description: The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
Study: NCT01160237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PandemrixTM
Description: One dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM/ Influsplit SSW® 2010/2011
Description: One dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM/ Influsplit SSW® 2010/2011
Description: One dose intramuscular injection
Study: NCT01566097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Decision Aids
Description: The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~1. Information on the risk of continued smoking and benefits of cessation~2. Messages that address common misbeliefs regarding smoking cessation services and medications~3. Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~1. Behavioral only~2. Nicotine replacement therapy~3. Bupropion~4. Varenicline
Study: NCT03866369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single oral dose at D-8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose at D-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose at D-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose at D-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanifibranor
Description: Single daily oral dose during 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single daily oral dose during 14 days
Study: NCT01084226

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rye-2008

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rye-2008
Study: NCT02830529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAD DASH
Description: Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet education
Description: The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet education
Description: The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
Study: NCT00855413

Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir
Description: 800 mg orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: 100 mg orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine
Description: 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
Study: NCT00825305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abbreviated Zagreb 2-1-1 schedule
Description: Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Essen 1-1-1-1-1 schedule
Description: Subjects received the standard Essen regimen.
Study: NCT03382769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Description: Unilateral implantation with a commercially approved Nucleus cochlear implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implantation
Description: Unilateral implantation with a commercially approved Nucleus cochlear implant
Study: NCT03124654

Intervention type: BEHAVIORAL
Intervention: Education
Description: Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
Study: NCT02872389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
Study: NCT00729638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
Study: NCT02806843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehab InterCap system and 3D Kinect
Description: The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
Study: NCT01907698

Intervention type: BEHAVIORAL
Intervention: Vaginal intercourse
Description: vaginal intercourse at least twice a week
Study: NCT01980004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Supplementation
Description: 20 mEq taken twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Education
Description: Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Education
Description: Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
Study: NCT01502592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery.
Study: NCT01059305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
Study: NCT03783676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Receive remifentanil bolus and infusion guided by an algorithm.
Study: NCT06178718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo will be administered once in each group.
Study: NCT01888653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification (ABM)
Description: The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control training (ACT)
Description: In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
Study: NCT03165084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: Person-centred interactive self-management support
Description: Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources.

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
Study: NCT03783676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Receive normal saline bolus and infusion guided by the remifentanil algorithm.
Study: NCT01251406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous administration for 8 hours a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1 Dose 1
Description: Daily subcutaneous administration for 8 hours a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1 Dose 2
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study: NCT00535379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
Study: NCT04625010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal holding
Description: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
Study: NCT03165084

Intervention type: OTHER
Group type: OTHER
Intervention: External comparison group
Description: External comparison groups in order to analyse possible Hawthorne effects.
Study: NCT03873454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sennheiser non-occlusive headphones
Description: Patients listened to music of their choice using non-occlusive headphones

Intervention type: DEVICE
Group type: OTHER
Intervention: Sennheiser non-occlusive headphones without music
Description: Patients wore non-occlusive headphones but had no music playing

Intervention type: OTHER
Group type: OTHER
Intervention: No Sennheiser non-occlusive headphones
Description: Patients did not wear non-occlusive headphones and did not listen to music
Study: NCT04530578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin sodium
Description: Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous Enoxaparine every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous Enoxaparine every 24 hours
Study: NCT04910633

Intervention type: OTHER
Intervention: COCA is an observational study based on retrospective data issued from patient medial file.
Description: The following parameters will be collected from the medical files of the patients involved in this study:~* Age~* Gender~* Cancer type~* Cancer Stage~* Cancer Treatment~* COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~* Living Status~* Attribution of Mortality to COVID status~* Comorbidities
Study: NCT00950482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AA
Description: In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WC
Description: Waiting Group
Study: NCT03723226

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Load Resistance Exercise
Description: Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance Exercise + BFR
Description: Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Study: NCT05585645

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimus (NNG-DEPO)
Description: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stimus (NNG-DEPO)
Description: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
Study: NCT01798342

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
Study: NCT04530604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (\>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course).